Hims & Hers Health: Still Undervalued
Hims & Hers Health:仍然被低估
1. Hims & Hers Health被认为估值偏低,预测市销率仅为3.5,尽管其年收入增长达88%并通过ZAVA拓展欧洲市场;2. 技术分析显示41美元存在强劲支撑,为买入良机,但高做空比例使轧空可能性较低;3. 风险包括法律问题及GLP-1药物销售下滑,但作者仍看好该股,并持续在当前价位增持。
Hims & Hers Health: Still Undervalued
U.S. IPO Weekly Recap: Quiet Week As IPO Market Gears Up For A Busy Fall